Compare
Cel-Sci Corp vs Champions Oncology, Inc. vs IN8BIO, Inc. vs Inmune Bio, Inc.
| Latest fiscal year | Cel-Sci Corp CVM | Champions Oncology, Inc. CSBR | IN8BIO, Inc. INAB | Inmune Bio, Inc. INMB |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2026-04-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $59.42M | n/a | $50.0K |
| Revenue growth (YoY) | n/a | +4.4% | n/a | +257.1% |
| Gross margin | n/a | 48.0% (computed) | n/a | n/a |
| Operating margin | n/a | -1.9% | n/a | n/m |
| Net margin | n/a | -2.0% | n/a | n/m |
| Net income | -$25.41M | -$1.18M | -$19.44M | -$45.93M |
| EPS (Diluted) | -$6.27 | -$0.08 | -$4.44 | -$1.86 |
| Operating cash flow | -$17.12M | -$4.47M | -$12.71M | -$22.58M |
| Free cash flow | -$17.16M | -$5.04M | n/a | -$23.62M |
| Cash & equivalents | n/a | n/a | n/a | $24.75M |
| Total assets | $28.16M | $26.99M | $32.28M | $32.35M |
| Total liabilities | $12.20M | $22.92M | $4.72M | $8.83M |
| Shareholders' equity | $15.96M | $3.94M | $27.56M | $23.52M |
| Return on year-end equity | -159.2% | -29.8% | -70.5% | -195.3% |
| Shares outstanding | 8.02M | 13.89M | 9.77M | 26.59M |
Revenue, most recent five fiscal years
| Fiscal year | Cel-Sci Corp | Champions Oncology, Inc. | IN8BIO, Inc. | Inmune Bio, Inc. |
|---|---|---|---|---|
| Latest | $264.0K Ended 2014-09-30 | $59.42M Ended 2026-04-30 | n/a | $50.0K Ended 2025-12-31 |
| 1 year earlier | $159.6K Ended 2013-09-30 | $56.94M Ended 2025-04-30 | n/a | $14.0K Ended 2024-12-31 |
| 2 years earlier | $254.6K Ended 2012-09-30 | $50.16M Ended 2024-04-30 | n/a | $155.0K Ended 2023-12-31 |
| 3 years earlier | $956.2K Ended 2011-09-30 | $53.87M Ended 2023-04-30 | n/a | $374.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $49.11M Ended 2022-04-30 | n/a | $181.0K Ended 2021-12-31 |